Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide for Recurrent or Refractory Pediatric CNS Tumors
NCT02415153Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2015
- Primary completion
- Jul 2019
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pomalidomide in central nervous system tumor, sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose / Recommended Phase II Dose at 28 days and Pharmacokinetics parameters of pomalidomide at Day 21. Started Jul 2015; status: completed.
02
Drugs
pomalidomide
03
Conditions
central nervous system tumor
Beyond the preview
Go deeper on NCT02415153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02415153.